Furthermore, the addition of TLR7 agonists progressed the proportion of M1 to M2 tumor-associated macrophages (TAMs) and promoted the infiltration of tumor-specific IFNγ -producing CD8+ T cells [164]. The gene discussed is CD8A; the disease is neoplasm.